Xilio Therapeutics, Inc.
XLO • NASDAQ
Xilio Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Rene Russo, with a market cap of $48.1M.
CEORene Russo
Next Earnings
Upcoming earnings announcement for Xilio Therapeutics, Inc.
Date
Thursday, May 7, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.35
Revenue Estimate
$7.5M
Earnings History
Past 12 earnings reports for Xilio Therapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 23, 2026 | Q4 2025 | $0.81Est: -$0.74 | +209.5% | $13.7MEst: $8.0M | +71.9% |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.11Est: -$0.03 | -266.7% | $19.1MEst: $21.8M | -12.7% | 10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.16Est: -$0.08 | -100.0% | $8.1MEst: $8.0M | +0.4% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.18Est: -$0.30 | +40.0% | $2.9MEst: $6.8M | -56.6% | 10-Q |
| Mar 11, 2025 | Q4 2024 | -$0.20Est: -$0.24 | +16.7% | $1.7M | — | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.22Est: -$0.25 | +12.0% | $2.3MEst: $3.3M | -31.4% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.24Est: -$0.23 | -4.3% | $2.4M | — | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.59Est: -$0.11 | -436.4% | -Est: $30.0M | -100.0% | 10-Q |
| Apr 1, 2024 | Q4 2023 | -$0.64Est: -$0.74 | +13.5% | - | — | — |
| Nov 9, 2023 | Q3 2023 | -$0.61Est: -$0.81 | +24.7% | - | — | — |
| Aug 14, 2023 | Q2 2023 | -$0.70Est: -$0.87 | +19.5% | - | — | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.83Est: -$0.89 | +6.7% | - | — | 10-Q |